Prevention of Post-discharge Venous Thromboembolism in Patients with Rheumatoid Arthritis Undergoing Knee or Hip Arthroplasty: a Continuing Matter of Debate

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2001 Sep 15

PMID 11557644

Citations 1

Authors

M T Nurmohamed

B A Dijkmans

Affiliations

Soon will be listed here.

Citing Articles

Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis.

Nurmohamed M, van Halm V, Dijkmans B Drugs. 2002; 62(11):1599-609.

PMID: 12109923 DOI: 10.2165/00003495-200262110-00003.

References

Ginsberg J, Turkstra F, Buller H, MacKinnon B, Magier D, Hirsh J . Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch Intern Med. 2000; 160(5):669-72. DOI: 10.1001/archinte.160.5.669. View

Colwell Jr C, Collis D, Paulson R, McCutchen J, Bigler G, Lutz S . Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am. 1999; 81(7):932-40. DOI: 10.2106/00004623-199907000-00005. View

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343(21):1520-8, 2 p following 1528. DOI: 10.1056/NEJM200011233432103. View

White R, Gettner S, Newman J, Trauner K, Romano P . Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med. 2000; 343(24):1758-64. DOI: 10.1056/NEJM200012143432403. View

Turpie A, Gallus A, Hoek J . A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001; 344(9):619-25. DOI: 10.1056/NEJM200103013440901. View

Crofford L . Cyclooxygenase inhibition and thrombogenicity. Am J Med. 2001; 110 Suppl 3A:28S-32S. DOI: 10.1016/s0002-9343(00)00683-5. View

van Heereveld H, Laan R, van den Hoogen F, Malefijt M, Novakova I, van de Putte L . Prevention of symptomatic thrombosis with short term (low molecular weight) heparin in patients with rheumatoid arthritis after hip or knee replacement. Ann Rheum Dis. 2001; 60(10):974-6. PMC: 1753387. DOI: 10.1136/ard.60.10.974. View

Schulman S, Henriksson K . Interaction of ibuprofen and warfarin on primary haemostasis. Br J Rheumatol. 1989; 28(1):46-9. DOI: 10.1093/rheumatology/28.1.46. View

Landefeld C, Rosenblatt M, Goldman L . Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med. 1989; 87(2):153-9. DOI: 10.1016/s0002-9343(89)80690-4. View

10.

Nurmohamed M, Rosendaal F, Buller H, Dekker E, Hommes D, Vandenbroucke J . Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 1992; 340(8812):152-6. DOI: 10.1016/0140-6736(92)93223-a. View

11.

van der Meer F, Rosendaal F, Vandenbroucke J, Briet E . Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993; 153(13):1557-62. DOI: 10.1001/archinte.153.13.1557. View

12.

Landefeld C, Beyth R . Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993; 95(3):315-28. DOI: 10.1016/0002-9343(93)90285-w. View

13.

Garcia Rodriguez L, Jick H . Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994; 343(8900):769-72. DOI: 10.1016/s0140-6736(94)91843-0. View

14.

Dahl O, Aspelin T, Arnesen H, Seljeflot I, Kierulf P, Ruyter R . Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res. 1995; 80(4):299-306. DOI: 10.1016/0049-3848(95)00180-y. View

15.

Planes A, Vochelle N, Darmon J, Fagola M, Bellaud M, Huet Y . Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996; 348(9022):224-8. DOI: 10.1016/s0140-6736(96)01453-5. View

16.

Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, DAngelo A . Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996; 348(9025):423-8. DOI: 10.1016/s0140-6736(96)01109-9. View

17.

Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S . Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996; 335(10):696-700. DOI: 10.1056/NEJM199609053351002. View

18.

Dahl O, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S . Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost. 1997; 77(1):26-31. View

19.

Noorman F, Bos R, Rijken D . Monoclonal antibodies against the human mannose receptor that inhibit the binding of tissue-type plasminogen activator. Thromb Haemost. 1997; 77(4):718-24. View

20.

Lassen M, Borris L, Anderson B, Jensen H, Skejo Bro H, Andersen G . Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res. 1998; 89(6):281-7. DOI: 10.1016/s0049-3848(98)00018-8. View